Who invested in Cerevance

3 rounds we have observed, with the 6 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Raised 6 months ago

Funding summaryUpdated 26 Oct 2026

$89Mraised across 3 rounds since 2016, from 3 sources

$22MSeries A$47MSeries B$20MSeries C

Latest round: Series C, $20MMay 2026
Biggest round: $47MSeries B · Apr 2024
Investors: 6

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20182020202220242026

$22MSeries A$47MSeries B$20MSeries C

First round: Series A, $22M
Biggest round: $47M
Usual gap between rounds: 7.3 years

The rounds

May 2026
Series C$20M2 returning
- Foresite Capital
- SV Health Investors
Source recorded
Apr 2024
Series B$47M4 new
Source recorded
Dec 2016
Series A$22M2 new
- Lightstone Ventures
- Takeda Pharmaceutical
Reported by FinSMEs

Founders and team

From Cerevance's own website: 8 on the team.

Rob MiddlebrookChief Financial Officer
Brett TruittVP, Technical Operations
Johnna SimõesVP, Marketing
Brad MargusChair
Craig ThompsonCheif Executive Officer
David LubnerIndependent Director
Jean GeorgeGeneral Partner
Robert MiddlebrookCheif Financial Officer

Who was in which round

The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.

Series A2016Series B2024Series C2026

Foresite CapitalSV Health Investors

Google Ventures

Casdin Capital

Lightstone VenturesTakeda Pharmaceutical

Everyone who backed them

Foresite CapitalPrivate equity2rounds

SV Health InvestorsVC firm2rounds

Google VenturesCorporate VC1round

Casdin CapitalVC firm1round

Lightstone VenturesVC firm1round

Takeda PharmaceuticalInvestment firm1round

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 3 firms list Cerevance as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.